Cyclooxygenase-mediated prostaglandin F2α is decreased in an elderly population treated with low-dose aspirin

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 72, Issue 4, 2005, Pages 227-233

  Helmersson, J ^a   Vessby, B ^a   Larsson, A ^b   Basu, S ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

13,14 DIHYDRO 15 OXOPROSTAGLANDIN F2 ALPHA; 8 ISOPROSTAGLANDIN F2 ALPHA; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; AMYLOID A PROTEIN; ANTIOXIDANT; C REACTIVE PROTEIN; INTERLEUKIN 6; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN F2 ALPHA DERIVATIVE; PROSTAGLANDIN SYNTHASE; TOCOPHEROL DERIVATIVE;

AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG EFFECT; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

EID: 14844331408     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2004.10.019     Document Type: Article

References (50)

1. Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration, BMJ 308 (1994) 81-106.
2. J.R. Vane Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs Nat. New Biol. 231 1971 232 235
3. J.B. Smith, and A.L. Willis Aspirin selectively inhibits prostaglandin production in human platelets Nat. New Biol. 231 1971 235 237
4. C. Patrono, G. Ciabattoni, and E. Pinca Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects Thromb. Res. 17 1980 317 327
5. G.J. Roth, N. Stanford, and P.W. Majerus Acetylation of prostaglandin synthase by aspirin Proc. Natl. Acad. Sci. USA 72 1975 3073 3076
6. 2-terminal serine of prostaglandin synthetase by aspirin J. Biol. Chem. 253 1978 3782 3784
7. C. Patrono Aspirin as an antiplatelet drug N. Engl. J. Med. 330 1994 1287 1294
8. R. De Caterina, D. Giannessi, and W. Bernini Low-dose aspirin in patients recovering from myocardial infarction. Evidence for a selective inhibition of thromboxane-related platelet function Eur. Heart J. 6 1985 409 417
9. J. Helmersson, B. Vessby, A. Larsson, and S. Basu Association of type 2 diabetes with cyclooxygenase-mediated inflammation and oxidative stress in an elderly population Circulation 109 2004 1729 1734
10. S. Bergström Prostaglandins members of a new hormonal system. These physiologically very potent compounds of ubiquitous occurrence are formed from essential fatty acids Science 157 1967 382 391
11. J.R. Vane Prostaglandins as mediators of inflammation Adv. Prostaglandin Thromboxane Res. 2 1976 791 801
12. D.A. Willoughby Heberden Oration, 1974. Human arthritis applied to animal models. Towards a better therapy Ann. Rheumatol. Dis. 34 1975 471 478
13. S. Basu, and H. Kindahl Development of a continuous blood collection technique and a detailed study of prostaglandin F2 alpha release during luteolysis and early pregnancy in heifers J. Vet. Med. A 34 1987 487 500
14. S. Basu Radioimmunoassay of 15-keto-13, 14-dihydro-prostaglandin F2alpha an index for inflammation via cyclooxygenase catalysed lipid peroxidation Prostaglandins Leukot. Essent. Fatty Acids 58 1998 347 352
15. S. Basu, and M. Eriksson Oxidative injury and survival during endotoxemia FEBS Lett. 438 1998 159 160
16. D.K. Mutschler, M.B. Eriksson, and B.G. Wikström Microdialysis-evaluated myocardial cyclooxygenase-mediated inflammation and early circulatory depression in porcine endotoxemia Crit. Care Med. 31 2003 1780 1785
17. I. Ikonomidis, F. Andreotti, E. Economou, C. Stefanadis, P. Toutouzas, and P. Nihoyannopoulos Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin Circulation 100 1999 793 798
18. M. Feldman, I. Jialal, S. Devaraj, and B. Cryer Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations a placebo-controlled study using a highly sensitive C-reactive protein assay J. Am. Coll. Cardiol. 37 2001 2036 2041
19. D. Feng, R.P. Tracy, I. Lipinska, J. Murillo, C. McKenna, and G.H. Tofler Effect of short-term aspirin use on C-reactive protein J. Thromb. Thrombolysis 9 2000 37 41
20. D. Steinberg, S. Parthasarathy, T.E. Carew, J.C. Khoo, and J.L. Witztum Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity N. Engl. J. Med. 320 1989 915 924
21. J.D. Morrow, K.E. Hill, R.F. Burk, T.M. Nammour, K.F. Badr, and L.J.d. Roberts A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase free radical-catalyzed mechanism Proc. Natl. Acad. Sci. USA 87 1990 9383 9387
22. S. Basu, and J. Helmersson Factors regulating isoprostane formation in vivo. Antioxidants and redox signalling Antioxid. Redox. Signal. 7 2005 221 225
23. J.D. Morrow, B. Frei, and A.W. Longmire Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage N. Engl. J. Med. 332 1995 1198 1203
24. M. Reilly, N. Delanty, J.A. Lawson, and G.A. FitzGerald Modulation of oxidant stress in vivo in chronic cigarette smokers Circulation 94 1996 19 25
25. G. Davi, P. Alessandrini, and A. Mezzetti In vivo formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia Arterioscler. Thromb. Vasc. Biol. 17 1997 3230 3235
26. N.K. Gopaul, E.E. Änggård, A.I. Mallet, D.J. Betteridge, S.P. Wolff, and J. Nourooz-Zadeh Plasma 8-epi-PGF2 alpha levels are elevated in individuals with non-insulin dependent diabetes mellitus FEBS Lett. 368 1995 225 229
27. H. Hedstrand A study of middle-aged men with particular reference to risk factors for cardiovascular disease Upsala J. Med. Sci. Suppl. 19 1975 1 61
28. L. Byberg, A. Siegbahn, L. Berglund, P. McKeigue, R. Reneland, and H. Lithell Plasminogen activator inhibitor-1 activity is independently related to both insulin sensitivity and serum triglycerides in 70-year-old men Arterioscler. Thromb. Vasc. Biol. 18 1998 258 264
29. S. Basu Radioimmunoassay of 8-iso-prostaglandin F2alpha an index for oxidative injury via free radical catalysed lipid peroxidation Prostaglandins Leukot. Essent. Fatty Acids 58 1998 319 325
30. M. Öhrvall, S. Tengblad, and B. Vessby Lower tocopherol serum levels in subjects with abdominal adiposity J. Intern. Med. 234 1993 53 60
31. G.J. Roth, and P.W. Majerus The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein J. Clin. Invest. 56 1975 624 632
32. S. Basu Endogenous inhibition of arachidonic acid metabolism in the endometrium of the sheep Prostaglandins Leukot. Essent. Fatty Acids 35 1989 147 152
33. H. Schweer, B. Watzer, H.W. Seyberth, and R.M. Nüsing Improved quantification of 8-epi-prostaglandin F2 alpha and F2-isoprostanes by gas chromatography/triple-stage quadrupole mass spectrometry partial cyclooxygenase-dependent formation of 8-epi-prostaglandin F2 alpha in humans J. Mass Spectrom. 32 1997 1362 1370
34. R. Ross Atherosclerosis - an inflammatory disease N. Engl. J. Med. 340 1999 115 126
35. G.A. FitzGerald, S. Austin, K. Egan, Y. Cheng, and D. Pratico Cyclo-oxygenase products and atherothrombosis Ann. Med. 32 2000 21 26
36. J. Claria, and C.N. Serhan Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions Proc. Natl. Acad. Sci. USA 92 1995 9475 9479
37. J.L. Wallace, and S. Fiorucci A magic bullet for mucosal protection... and aspirin is the trigger! Trends Pharmacol. Sci. 24 2003 323 326
38. T. Takano, S. Fiore, J.F. Maddox, H.R. Brady, N.A. Petasis, and C.N. Serhan Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation evidence for anti-inflammatory receptors J. Exp. Med. 185 1997 1693 1704
39. P.M. Ridker, M. Cushman, M.J. Stampfer, R.P. Tracy, and C.H. Hennekens Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men N. Engl. J. Med. 336 1997 973 979
40. P.M. Ridker, N. Rifai, M.J. Stampfer, and C.H. Hennekens Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men Circulation 101 2000 1767 1772
41. J. Danesh, P. Whincup, and M. Walker Low grade inflammation and coronary heart disease prospective study and updated meta-analyses BMJ 321 2000 199 204
42. J. Musial, A. Undas, P. Gajewski, M. Jankowski, W. Sydor, and A. Szczeklik Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia Int. J. Cardiol. 77 2001 247 253
43. F. Cipollone, G. Ciabattoni, and P. Patrignani Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina Circulation 102 2000 1007 1013
44. X. Shi, M. Ding, and Z. Dong Antioxidant properties of aspirin characterization of the ability of aspirin to inhibit silica-induced lipid peroxidation DNA damage, NF-kappaB activation, and TNF-alpha production, Mol. Cell Biochem. 199 1999 93 102
45. S. Basu Oxidative injury induced cyclooxygenase activation in experimental hepatotoxicity Biochem. Biophys. Res. Commun. 254 1999 764 767
46. J. Helmersson, and S. Basu F(2)-isoprostane and prostaglandin F(2 alpha)metabolite excretion rate and day to day variation in healthy humans Prostaglandins Leukot. Essent. Fatty Acids 65 2001 99 102
47. Q. Jiang, S. Christen, M.K. Shigenaga, and B.N. Ames Gamma-tocopherol, the major form of vitamin E in the US diet, deserves more attention Am. J. Clin. Nutr. 74 2001 714 722
48. G. Davi, M.T. Guagnano, and G. Ciabattoni Platelet activation in obese women role of inflammation and oxidant stress JAMA 288 2002 2008 2014
49. P.M. Ridker, N. Rifai, M.A. Pfeffer, F. Sacks, and E. Braunwald Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators Circulation 100 1999 230 235
50. N. Chiang, E.A. Bermudez, P.M. Ridker, S. Hurwitz, and C.N. Serhan Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial Proc. Natl. Acad. Sci. 101 2004 15178 15183